Sanofi veteran Christopher Winter has been appointed as the new chief of R&D at drug discovery biotech Silicon, becoming the latest in an increasingly long line of Big Pharma executives to join the early-stage life science stream.
Winter comes to the Boston-based company from Sanofi, where since 2013 he led its U.S. oncology research as site lead and research cluster head on overcoming immunosuppression.
This comes as Sanofi has once again been retooling its cancer R&D, bringing a deeper focus into key oncology areas after seemingly looking to scale down just a few years back.
Winter, also a Blueprint Medicines, Merck Research Laboratories and Exelixis alumnus, will work with Silicon and its “integrated physics-based drug discovery,” where it is looking to create small molecule therapeutics for diseases with challenging protein targets that are difficult to drug.
“Silicon Therapeutics has assembled a world-class team applying an industry-leading platform to address fundamental challenges for designing next-generation, breakthrough therapeutics,” said Winter.
“I’m excited to join Silicon Therapeutics’ mission that joins integrated excellence in physics-based simulations, chemistry and disease biology focused on making drugs that matter for patients.”
By Ben Adams
Source: Fierce Biotech
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.
